5/5/2014 8:13:03 AM
Abbott Laboratories (ABT.N) is considering selling a big chunk of its mature drugs, joining a list of large drugmakers seeking to sell their older products in an effort to focus on high-growth areas, people familiar with the matter said. Abbott's portfolio of mature drugs being reviewed for sale has around $2 billion in annual revenue and could fetch more than $5 billion, the people said. The U.S. drugmaker is working with Morgan Stanley (MS.N) to find a buyer for the off-patent, or established products, the people added, asking not to be identified because the matter is confidential.
Help employers find you! Check out all the jobs and post your resume.
comments powered by